^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Osteosarcoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + doxorubicin hydrochloride (Topoisomerase II inhibitor) + methotrexate (THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
11/20/2020
Excerpt:
Osteosarcoma: First-line therapy (primary/neoadjuvant/adjuvant therapy or metastatic disease)…Preferred Regimens…MAP (high-dose methotrexate, cisplatin, and doxorubicin) (Category 1)
